Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

Oppenheimer analyst Matthew Biegler reiterated a Hold rating on Day One Biopharmaceuticals (DAWN – Research Report) yesterday. The company’s ...

Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Oric Pharmaceuticals (ORIC – Research Report) yesterday and set a price target ...

Ieq Capital LLC has reduced its stake in Regeneron Pharmaceuticals by 28%, selling 1,496 shares in the fourth quarter. Other ...

In Regeneron Pharmaceuticals Inc.’s phase I/II Chord study of 12 children with genetic hearing loss, 10 out of 11 have shown improvements after being treated with a gene therapy. “What is really ...

DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...

On February 18, 2025, a panel of the U.S. Court of Appeals for the First Circuit unanimously decided that in order to transform an ...

This was the stock's sixth consecutive day of gains.

The First Circuit has issued its long-anticipated opinion in United States v. Regeneron Pharmaceuticals, Inc., clarifying the ...

On February 18, 2025, the United States Court of Appeals for the First Circuit issued its opinion in United States v.

The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...

Last week, the First Circuit Court of Appeals issued its long-awaited decision in United States v. Regeneron Pharmaceuticals with ...